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Abstract
Background: Patients with chronic kidney disease (CKD) are at increased risk for inappropriate or potentially harmful
prescribing. The aim of this study was to examine whether a multifaceted intervention including the use of a software
programme for the estimation of creatinine clearance and recommendation of individual dosage requirements may
improve correct dosage adjustment of relevant medications for patients with CKD in primary care.
Methods: A cluster-randomized controlled trial was conducted between January and December 2007 in small primary
care practices in Germany. Practices were randomly allocated to intervention or control groups. In each practice, we
included patients with known CKD and elderly patients (≥70 years) suffering from hypertension. The practices in the
intervention group received interactive training and were provided a software programme to assist with individual
dose adjustment. The control group performed usual care. Data were collected at baseline and at 6 months. The
outcome measures, analyzed across individual patients, included prescriptions exceeding recommended maximum
daily doses, with the primary outcome being prescriptions exceeding recommended standard daily doses by more
than 30%.
Results: Data from 44 general practitioners and 404 patients are included. The intervention was effective in reducing
prescriptions exceeding the maximum daily dose per patients, with a trend in reducing prescriptions exceeding the
standard daily dose by more than 30%.
Conclusions: A multifaceted intervention including the use of a software program effectively reduced inappropriately
high doses of renally excreted medications in patients with CKD in the setting of small primary care practices.
Trial registration: Current Controlled Trials ISRCTN02900734
Background
Chronic kidney disease (CKD) is a common and costly
condition. In the United States, the estimated prevalence
for chronic renal impairment in adults is 13% [1,2], and a
similar figure is assumed for Germany. 6.4% of Medicare
health expenditures in the U.S. are spent for CKD patients
[3]. Major risk groups are patients with hypertension, dia-
betes, obesity, and dyslipidemia [4,5]. Prevalence of CKD
rises exponentially in the elderly [6], and has been shown
to be as high as 48% in patients over 70 years [7]. This
is attributed to an age-related loss of nephron func-
tion [8] and a higher prevalence of predisposing risk
factors (e.g. hypertension, diabetes) in older adults [7].
Other comorbid conditions common in elderly popula-
tions and associated with CKD are coronary artery disease,
peripheral vascular and cerebrovascular disease with cog-
nitive impairment. Comorbidities such as prostate hyper-
trophy and congestive heart failure result in a higher risk
for acute kidney injury and kidney failure [7]. Conversely,
CKD is an independent risk factor for cardiovascular dis-
ease and all-cause mortality [9].
In an aging population the incidence of CKD will likely
continue to rise [10]. Early detection, appropriate treat-
ment of risk factors, and timely referral to a nephrologist
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morbidity and mortality from cardiovascular disease,
and lower costs [4,11]. The care family physicians pro-
vide to populations at risk puts them in a position to
help detect CKD early and prevent progression [12]. De-
tection of CKD requires estimation of creatinine clear-
ance, because the measurement of serum creatinine
alone can be misleading, especially in elderly populations
[13,14]. However, a study found that 86% of family phy-
sicians only took serum creatinine concentration into
account when prescribing drugs for elderly patients [8].
If impaired renal function is detected, patients may re-
quire a dosage reduction of renally excreted drugs to
avoid accumulation and adverse drug reactions [15-17].
However, recommendations on dosage adjustment are
missing in up to 70% of the summaries of product char-
acteristics provided by the pharmaceutical industry, and
in other information sources available to family physi-
cians [18], leading to the prescription of inappropriately
high medication dosages in primary care [19].
Most interventions shown to be effective in improving
correct dosage adjustment of medications in CKD patients
involved inpatient settings, such as concurrent feedback
by pharmacists [20,21], or the integration of a decision
support system (CDSS) into a computerized physician
order entry (CPOE) system [22,23]. However, these inter-
ventions appear less feasible in small, isolated primary
care settings where personnel and financial resources
are limited [24].
Similar to Germany, 26% of primary care practices in
the United States are solo or 2-partner practices, and
22% are located in rural areas with limited access to
clinical pharmacists [25]. 46% of American and 72% of
German family physicians have an electronic health record
(EHR), but the availability of decision support is limited
[26]. In order to take advantage of their prime position to
detect and manage patients with impaired renal function,
family physicians need simple and inexpensive tools to
estimate glomerular filtration rate, adjust medications cor-
rectly, and educate patients under the time and financial
constraints of daily practice. Therefore, the objective of
this study was to evaluate whether a primary care-based
multifaceted intervention, including interactive training
for family physicians and the use of a software programme
for the estimation of renal function and corresponding
dosage adjustment, might be effective in reducing in-
appropriate prescriptions in patients with impaired renal
function.
Methods
Ethics statement
The institutional review board of the Goethe University
Frankfurt approved the study protocol on September 18,
2006. All participants provided written informed consent.
Setting and participants
All 1,876 family physicians registered with the Association
of Statutory Health Insurance Physicians in South Hesse,
Germany (mandatory registration) were mailed a letter
informing them of the trial and inviting them to partici-
pate in an informational meeting. As the registration list
contained only names and addresses, we ascertained eli-
gibility during the informational meetings or when a
physician contacted the study team directly. We stopped
recruiting when the required sample was enrolled, even
though more practices were interested in participating.
This pragmatic recruitment procedure has been adopted
in other cluster-randomized controlled trials in German
primary care settings (e.g. [27]) Inclusion criteria for prac-
tices were registration as a family physician without
specialization and availability of a computer in the con-
sulting room. We excluded practices which already used a
software programme for dosage adjustment in CKD.
We included patients with an estimated glomerular
filtration rate (GFR) <50 ml/min and a diagnosis of
chronic renal impairment (ICD-10 code N18.- or N19.-),
as well as elderly patients (≥70 years) suffering from
hypertension (ICD-10 code I10.-), thus defining an im-
portant risk group. Exclusion criteria were end-stage
renal disease requiring dialysis, palliative care, and per-
sons who were not regular patients of the study practice.
Randomization and intervention
Practices identified eligible patients and sent a list of
patient pseudonyms to the Institute of General Practice
at Goethe-University Frankfurt (IfA). From this list, 10
patients per practice were selected by the study team
using random numbers produced by SPSS (Version 15.0,
SPSS Sciences, Chicago, USA). The same method was
employed to allocate practices to intervention and con-
trol group in a 1:1 ratio without further stratification.
Blinding practices to their group allocation was not feas-
ible because of the nature of the intervention.
The multifaceted intervention consisted of 1) an inter-
active 1-hour workshop for physicians on detection and
management of CKD, 2) provision of a desktop checklist
of medications to be reduced or avoided in patients with
CKD, 3) provision of patient information leaflets, and 4)
training in the use of the software “DOSING” (accessible
at www.dosing.de). The software DOSING contains an in-
formation database on fractional renal excretion of cur-
rently >800 compounds, allows quick and easy estimation
of a patient’s creatinine clearance, and subsequently esti-
mates individual dosage requirements. Depending on the
extent of renal impairment, recommendations may be to
avoid a drug (contraindication) or to reduce the dose on
the basis of Dettli’s rules to avoid excessive exposure and
potential toxicity [16,28]. In the case of metformin, the
programme allowed calculation of an individual dose, but
Erler et al. BMC Family Practice 2012, 13:91 Page 2 of 8
http://www.biomedcentral.com/1471-2296/13/91also noted that current drug labels regard the use of met-
formin as inappropriate in patients with renal impairment.
The software is continuously updated by the Depart-
ment of Clinical Pharmacology and Pharmacoepidemiol-
ogy, University Hospital Heidelberg, Germany.
Linking the DOSING software directly to the study
practices’ electronic health records (EHR) was not feas-
ible, because of the many different practice software
systems in use. Therefore, the intervention practices
received a stand-alone CD version, and the physicians
were required to manually enter data to calculate cre-
atinine clearance and dose modifications. During the
intervention period, they received monthly telephone
reminders to use the programme.
Family physicians in the control group did not receive
any training or materials on CKD and were advised to
continue to treat their patients as before (usual care). All
written material used in this study was translated into
English and is available from the authors on request.
Outcomes
The primary and secondary outcomes evaluated at six
months were the number of patients receiving at least
one prescription exceeding 1) the recommended standard
d a i l yd o s a g eb ym o r et h a n3 0 %a n d2 )t h er e c o m m e n d e d
maximum daily dose. Dose requirements for a patient were
calculated as previously described [20]. Briefly, the software
programme DOSING calculated a percentage by which the
standard daily or maximum daily dose given to a patient
with normal renal function should be reduced on the basis
of the patient’s estimated creatinine clearance. We chose
these outcomes rather than the number of prescriptions
exceeding the recommended dosage because one overdosed
drug is sufficient to potentially harm the patient.
Further secondary outcomes were the number of
patients with prescriptions that are potentially dangerous
or contraindicated in CKD patients such as metformin,
nitrofurantoin, or allopurinol.
Data collection
Family physicians collected data from case report forms at
baseline and at 6 months. The forms were pilot-tested and
revised by three of our teaching practices. They contained
questions on patients’ demographic and clinical data, such
as present medication, weight, and serum creatinine. All
identifying patient data from the study practices was pseu-
donymized, i.e. only the study practice was able to identify
patients. For quality assurance, the data was entered twice
into a Microsoft Access database version 2000 (Microsoft
Corp., Redmond, Washington, USA).
Sample size calculation
Sample size was calculated on the basis of the primary out-
come. Using patients as the unit of analysis, we estimated
that at least 366 patients (183 per group) were required to
detect a 15% reduction (from 50% to 35% based on results
from previous studies [21,23]) with a power of 1−β=0.80
by means of a continuity corrected χ
2-test at a 0.05 two-
sided significance level. Assuming an intra-cluster correl-
ation coefficient (ICC) of 0.01 at practice level [29] and an
average cluster size of 10, we estimated a design effect of
D=1+(10–1) x 0.01=1.09. Thus, to have adequate power,
the sample size had to be adjusted to 400 patients (200 per
group) [30]. With 10 patients per practice, we needed to
include 40 practices (20 per arm). To allow for 10% lost to
follow-up, we increased this number to 46 practices (23 in
each arm).
Statistical analysis
Primary efficacy analysis was a comparison between
intervention and control groups at six months without
and with adjusting for the following variables: underlying
diagnosis, gender, patient’s age, creatinine value, and
proportion of patients with at least one prescription
exceeding the recommended dose at baseline. Missing
values for binary outcome variables were imputed with 0
(= not exceeding recommended dose) in both groups.
Differences between groups were analyzed by means of
generalized estimation equations (GEEs), which take
clustering by practice into account. We used empirical-
based standard error estimates and set the significance
level to 0.05 (two-sided). We calculated odds ratios (OR)
and corresponding 95% confidence intervals (CI). Statis-
tical analyses were carried out with SAS version 9.1
(SAS Institute, Cary, USA).
Results
We assessed 55 practices for eligibility, and excluded 2
practices because they did not meet the inclusion cri-
teria. 7 practices withdrew consent because of time con-
straints. 46 practices were randomized into intervention
(n=23) and control group (n=23). 2 intervention prac-
tices dropped out without providing any baseline data
and 1 intervention practice dropped out during the trial.
No practice assigned to usual care crossed over to inter-
vention or vice versa (Figure 1). We included data from
21 intervention and 23 control practices in the analysis.
The participating physicians recruited 404 study
patients (198 in the intervention and 206 in the control
group). 211 (52.2%) patients had a diagnosis of CKD,
whereas 193 (47.8%) had a primary diagnosis of hyper-
tension and were newly diagnosed with CKD. We col-
lected follow-up data from 384 (95.1%) of the patients at
6 months.
Demographic and clinical characteristics
Study practices in intervention and control group were
well balanced for physicians’ age, sex, specialty (family
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(Table 1). The control group contained slightly more
family physicians from an urban setting.
Patients in the two study arms were well balanced for
weight, serum creatinine values, estimated creatinine
clearances, mean number of prescriptions per patient,
and primary diagnosis (renal impairment/hypertension).
However, patients in the intervention group were slightly
older and more often male (Table 2).
Clinical outcomes
Patients with potentially dangerous or contraindicated
medications
At baseline we registered 2,784 prescriptions of which 588
(21%) required special consideration in CKD. Of these, 270
(46%) were for angiotensin converting-enzyme inhibitors
or angiotensin receptor blockers, 77 (13%) for allopurinol,
61 (10%) for antibiotics such as ciprofloxacin, amoxicillin,
clavulanic acid, cephalosporins, and 15 (3%) for metformin.
There was no significant change in the number of pre-
scriptions overall and per patient at 6 months.
Table 3 displays the number of patients after 6 months
receiving medications with a high potential for adverse
drug reactions in renal impairment. At baseline, 1 pa-
tient had a prescription for nitrofurantoin and 4 patients
for metformin in the intervention group versus 11 in the
control group. 22/40 patients with a prescription for
allopurinol in the intervention group (55%) and 17/37 in
the control group (46%) exceeded the recommended
standard daily dose. At 6 months, this had been reduced
by 18% in the intervention group compared with 1% in
the control group. None of the between-group differ-
ences at 6 months were statistically significant.
Patients with prescriptions exceeding the recommended
daily dose
The proportion of patients receiving one or more pre-
scriptions exceeding the recommended maximum daily
dose was significantly lower in the intervention group
compared to the control group after 6 months (19.2% vs.
34.5%; OR=0.45, 95% CI: 0.29 to 0.70; p<0.001). This
intervention effect remained statistically significant even
after adjustment for the proportion of patients with at
least one prescription exceeding the recommended max-
imum daily dose at baseline and further baseline covari-
ates such as patient’s age, gender, underlying diagnosis,
Figure 1 Flowchart of study practices and patients.
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vention recipients receiving one or more prescriptions
exceeding the recommended standard daily dose by
more than 30% was lower than in the control group
(47.5% vs. 58.7%; OR=0.64, 95% CI: 0.41 to 0.98;
p=0.040). However, this difference was not significant
after adjustment for baseline covariates (Table 4). A
sensitivity analysis of only complete cases revealed no
difference in results (data not shown). Because the sam-
ple size calculation was based on the estimated effect
size of the primary outcome, we did not perform any
statistical analyses for the overall number of prescrip-
tions shown above.
Discussion
Our intervention reduced the proportion of patients with
prescriptions exceeding the recommended maximum
daily dose, with a trend in reducing the proportion of
patients with at least one prescription exceeding the
recommended standard daily dose by more than 30%.
Most prescriptions exceeding the maximum or standard
daily dose were ACE-inhibitors (ACEI) and angiotensin-
receptor blockers (ARB).
A sensitivity analysis excluding these drugs failed to
show a significant reduction of the recommended daily
maximum dose at 6 months (data not shown). This sug-
gests that the intervention effect was mostly related to
ACEI and ARB.
Studies show that treatment with ACEI and ARB
reduces the progression of CKD [9], e.g. Benazepril was
associated with a 52% reduction in the level of protein-
uria and a 23% reduction in the rate of decline in renal
function [31]. While lower doses may be sufficient to
treat hypertension [32,33], dose escalation particularly in
CKD may be beneficial due to a nephroprotective effect
[31,34]. Although ACEI and ARB have a wide thera-
peutic margin, high doses bear a risk of hyperkalemia,
hypotension, and acute deterioration of renal function
[35]. Therefore, special attention is required when start-
ing these drugs. In order to account for this complex
situation, the DOSING programme provided informa-
tion on ACEI/ARB dosage in a text format, including
the specific recommendations for patients with CKD or
hypertension. At the same time it allowed the calcula-
tion of an individual dose reduction for patients with
hypertension.
Table 1 Baseline characteristics of participating family physicians by intervention and control group
Variable Intervention group Control group
Total N 21 23
Age [years], mean (SD) 47.8 (7.5) 50.2 (8.1)
Male [N] (%) 11 (52.4) 16 (69.9)
Geographical location urban [N] (%) 5 (23.8) 11 (47.8)
Single-handed practice [N] (%) 12 (57.1) 14 (60.9)
Practice size (patients per quarter) mean (SD) 1238 (718) 1487 (771)
<500 patients/quarter [N] (%) 2 (9.5) 0 (0)
500–1000 patients/quarter [N] (%) 5 (23.8) 7 (30.4)
1000–1500 patients/quarter [N] (%) 8 (38.1) 5 (21.7)
>1500 patients/quarter [N] (%) 6 (28.6) 11 (47.8)
SD = standard deviation.
Table 2 Baseline characteristics of study patients by intervention and control group
Variable Intervention group
(N=198 patients)
Control group
(N=206 patients)
GEE model
p value
Male [N] (%) 81 (40.9) 63 (30.6) 0.033
Age [years] mean (SD) 81.4 (5.6) 79.5 (8.7) 0.005
Weight [kg] mean (SD) 70.6 (12.5) 71.8 (14.1) 0.376
Serum creatinine [mg/dl] mean (SD) 1.47 (0.44) 1.52 (0.55) 0.348
Estimated creatinine clearance [ml/min] mean (SD) 38.8 (7.8) 39.0 (8.2) 0.733
Diagnosed hypertension [N] (%) 97 (49.0) 96 (46.6) 0.775
Prescriptions per patient mean (SD) 6.7 (3.0) 7.1 (3.1) 0.318
Prescriptions per patient requiring dose reduction
mean (SD)
1.4 (0.9) 1.5 (1.1) 0.124
SD = standard deviation.
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programme reduced the dose below the maximum but
kept it above the standard daily dose recommended for
patients. A further sensitivity analysis showed that this
was unrelated to the primary diagnosis of the patient
(CKD or hypertension; data not shown). A possible ex-
planation for this could be that the information provided
by the programme was too complex and physicians were
not certain which patients required a dose reduction.
In CKD patients, metformin may cause life-threatening
lactic acidosis [36], nitrofurantoin peripheral neuritis [37],
and a standard daily dose of 300 mg allopurinol may result
in a hypersensitivity syndrome [38]. No patient had been
prescribed nitrofurantoin and fewer patients than in other
studies [39] were prescribed excessive metformin doses
and, thus, differences between intervention and control
group were not significant. However, the intervention
group showed an 18% reduction in high dose allopurinol
prescriptions.
These results suggest that DOSING may be effective
in correcting dosing errors that are due to lack of know-
ledge or awareness (e.g. of serious adverse effects) and
for which the evidence provided is unambiguous, but
further studies with larger sample sizes are necessary to
confirm these findings.
Most previously published evidence on effective inter-
ventions to improve correct dosage adjustment in CKD
patients comes from inpatient settings [20,21,23], even
though dosage-related medication errors are equally
relevant in outpatient primary care settings [40]. Clinical
decision support systems (CDSS) have been successful in
reducing medication errors and adverse drug events in
inpatient settings [41-44]. In primary care, CDSS has
also shown benefits, but variability among the types and
methods of implementation and inconsistent use was
noted [45]. Rapid and easy access to the requested infor-
mation [46,47] and patient-specific advice [48] are im-
portant prerequisites for the use of CDSS in busy
practices. The strength of the DOSING programme is
that it provides patient-specific prescribing advice at the
point of care, which has the potential to improve atten-
tion and user response [48].
In a concomitant qualitative study reported elsewhere
[49], we performed telephone interviews with family
physicians in the intervention group in order to assess
usability and the content of the programme. Participat-
ing physicians found the content of DOSING generally
helpful and informative, and reported that its use
improved their awareness of patients with impaired renal
function.
As a CD version, DOSING proved feasible and effect-
ive in small, not fully computerized family practices; yet
the intervention effect may be larger if DOSING is inte-
grated into the EHR with a direct link to the medication
and the patient information needed to calculate creatin-
ine clearance.
Feasibility and effectiveness of the intervention may be
improved if medication checks, implemented as a con-
tinuous background process, would create alerts when
appropriate during the prescription of drugs. However,
most available commercial EHR systems currently lack
the functionalities to provide decision support [50].
There are several possible limitations of the study.
First, selection bias, because the participating practices
might have been especially motivated to improve pre-
scribing in CKD patients, therefore introducing a study ef-
fect in control practices. In Hesse, physicians are required
to participate in pharmacotherapy quality circles regularly.
The infrequent prescription of potentially dangerous med-
ications suggests that both groups were conscious of their
Table 3 Patients with potentially dangerous or contraindicated medications at 6 months by intervention and control
group
Variable Intervention group (N=198 patients) Control group (N=206 patients)
Metformin, proportion (%) 6/198 (3.0) 9/206 (4.4)
Nitrofurantoin, proportion (%) 0/198 (0.0) 0/206 (0.0)
Allopurinol, proportion (%) 38/198 (19.2) 40/206 (19.4)
Allopurinol exceeding recommended standard dose, proportion (%) 14/38 (36.8) 18/40 (45.0)
Table 4 Patients with prescriptions exceeding the recommended daily dose at 6 months by intervention and control
group
Variable Intervention
group (N=198)
Control
group (N=206)
Estimated model
adjusted ICC
Adjusted
OR (95% CI)
p-value
Patients with ≥1 prescription exceeding
recommended maximum dose [N] (%)
38 (19.2) 71 (34.5) 0.001 0.46 (0.26;0.82) 0.008
Patients with ≥1 prescription exceeding
recommended standard dose by >30% [N] (%)
94 (47.5) 121 (58.7) 0.039 0.66 (0.36;1.21) 0.180
Adjusted for underlying diagnosis, age, gender, serum creatinine, N patients with ≥1 prescription exceeding recommended maximum or standard dose at
baseline.
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may underestimate the real potential of the intervention
in less well trained primary care practices.
Second, an intervention period of 6 months is rela-
tively short. Further studies are needed to evaluate the
long-term effects of the intervention.
Third, our study did not evaluate clinical outcomes for
patients such as adverse effects of drugs requiring dose
reduction, and we did not assess confounding factors
such as the patients’ compliance to drug therapy. How-
ever, our study aimed to assess whether the use of a soft-
ware tool for the estimation of renal function and the
provision of information on corresponding dosage ad-
justment is feasible in busy small primary care practices,
and whether it can effectively change prescription behav-
iour of family physicians for patients with impaired renal
function. In order to measure these effects, we selected
process rather than outcome parameters, such as the
number of inappropriate prescriptions for these patients.
Future studies should assess the effect of the interven-
tion on patient-related clinical outcomes.
Finally, unlicensed use of metformin in patients with
mild renal impairment is currently subject to debate [51]
making automated decision support difficult without
considering the particularities of the individual case. In
these situations our tool provided both, information on
the labelled contraindication as well as guidance for dose
adjustment to minimize the risk of accumulation.
Similarly, strict dose reductions of ACEI and ARB by
an automated decision support system will only be ap-
propriate if relevant patient characteristics such as the
indication (hypertension vs. renal protection in CKD)
are available and considered.
Conclusions
In conclusion, a multifaceted intervention using a soft-
ware programme for the estimation of creatinine clear-
ance and subsequent dose adjustment is effective in
detecting CKD in at-risk patients and reducing inappro-
priately high doses of renally excreted medications in
patients with CKD in small primary care practices. Fur-
ther research should assess additional costs and benefits
if decision support is fully integrated in the EHR.
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